Global Emphysema Treatment Medication Market Growth (Status and Outlook) 2024-2030

Global Emphysema Treatment Medication Market Growth (Status and Outlook) 2024-2030

Emphysema is a chronic and progressive lung condition characterized by damage to the air sacs in the lungs, known as alveoli. This damage leads to the deterioration of the lung tissue and results in decreased elasticity, making it difficult to breathe. The primary cause of emphysema is long-term exposure to irritants, most commonly cigarette smoke, although other factors such as air pollution and genetic predisposition can also contribute. Symptoms of emphysema include shortness of breath, chronic coughing, wheezing, and tightness in the chest. Treatment for emphysema focuses on managing symptoms and slowing down the progression of the disease. Medication is the therapeutic interventions for emphysema treatment.

The global Emphysema Treatment Medication market size is projected to grow from US$ 4174 million in 2024 to US$ 5102 million in 2030; it is expected to grow at a CAGR of 3.4% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Emphysema Treatment Medication Industry Forecast” looks at past sales and reviews total world Emphysema Treatment Medication sales in 2022, providing a comprehensive analysis by region and market sector of projected Emphysema Treatment Medication sales for 2023 through 2029. With Emphysema Treatment Medication sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Emphysema Treatment Medication industry.

This Insight Report provides a comprehensive analysis of the global Emphysema Treatment Medication landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Emphysema Treatment Medication portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Emphysema Treatment Medication market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Emphysema Treatment Medication and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Emphysema Treatment Medication.

Surge in prevalence of emphysema and rise in number of smokers are expected to drive the growth of the emphysema treatment market. For instance, according to 2024 article by American Lung Association, it was estimated that over 3 million people in the U.S. have been diagnosed with emphysema. Furthermore, according to a report by Foundation for a Smoke-Free World, it was reported that prevalence of smoking in India was estimated to be 4.6%.

This report presents a comprehensive overview, market shares, and growth opportunities of Emphysema Treatment Medication market by product type, application, key players and key regions and countries.

Segmentation by Type:
Bronchodilators
Steroids
Others

Segmentation by Application:
Hospitals
Homecare
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Bronchodilators
Steroids
Others

Segmentation by Application:
Hospitals
Homecare
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Emphasys Medical
Pfizer
Uptake Medical
Inogen, Inc
Viatris Inc
Boehringer Ingelheim International GmbH
Novartis AG
AstraZeneca
Orion Corporation
Teva Pharmaceutical Industries Ltd
Verona Pharma Plc
GlaxoSmithKline Plc
Pulmonx
Bioxyne
Intrexon
Icure Pharmaceuticals
Kamada

Please note: The report will take approximately 2 business days to prepare and deliver.